Itch results demonstrated in a phase 3 study of patients 12+ years of age1-3
Not an actual patient.
≈4x
As many patients
taking DUPIXENT achieved itch improvement at Week 16 vs placebo1-3
taking DUPIXENT achieved itch
improvement at Week 16 vs
placebo1-3
AD-HAFT 12+ YEARS
≥4-point reduction in
hand and/OR foot Peak
PruritUs NRS AT WEEK 16
(secondary endpoint)1-3
hand and/OR foot Peak
PruritUs NRS AT WEEK 16
(secondary endpoint)1-3
Definitive conclusions cannot be made for time points earlier than Week 16 as those data were not multiplicity controlled and P value was nominal
All DUPIXENT-treated patients in AD-HAFT received DUPIXENT monotherapy for their hand and/or foot lesions3
- Dosing for DUPIXENT in this study was consistent with the approved dosage in the Prescribing Information1,3
Explore more Peak Pruritus NRS efficacy results
VIEW ADULT DATA
VIEW ADOLESCENT
(12 TO 17 YEARS) DATA VIEW CHILD
(6 TO 11 YEARS) DATA VIEW INFANT TO PRESCHOOLER
(6 MONTHS TO 5 YEARS) DATA
(12 TO 17 YEARS) DATA VIEW CHILD
(6 TO 11 YEARS) DATA VIEW INFANT TO PRESCHOOLER
(6 MONTHS TO 5 YEARS) DATA
NRS, numerical rating scale; Q2W, once every 2 weeks.
READY TO PRESCRIBE DUPIXENT?